Molecular diagnostics laboratory P23 Labs reported on Friday the availability of its new P23 Respiratory ONE test to detect respiratory illnesses that share symptoms with COVID-19 when test results for COVID-19 are negative and the patient is still not healthy.
The company added that the P23 Respiratory ONE can detect the common cold, five different Influenza strains and five Coronavirus strains including COVID-19. The test results are available 48 hours from lab receipt.
According to the company, the P23 Respiratory ONE takes a single COVID-19 sample, whether it is the non-invasive saliva sample or the nasal swab sample. The kits are shipped directly to patients to allow sample collection from the comfort of their own home.
If anyone is presenting COVID-19 symptoms and working with their physician to obtain a COVID-19 order, the patient should also tell their physician that they would like to have a test that identifies what illness they do have if it is not COVID-19, concluded the company.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA